EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

Michael J Wilson, Antonius W Schurink, Yvonne Schrage, Michel W J M Wouters, Winan J van Houdt, Dirk J Grunhagen, Hans V van Thienen, Bart A van de Wiel, Bernies van der Hiel, Anke M J Kuijpers

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116691 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Michael J Wilson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntibodies, Monoclonal, HumanizedPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Lymph NodesSkin NeoplasmsAntineoplastic Agents, ImmunologicalHumansNeoadjuvant TherapyRetrospective StudiesNetherlandsMiddle AgedFemaleMaleRadiopharmaceuticalsAgedLymphatic MetastasisAdultPredictive Value of TestsNeoplasm StagingTreatment Outcome

Stichwörter der Autor:innen

MelanomaNeoadjuvant immunotherapyPETCT

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18RadiopharmaceuticalsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: a.kuijpers@nki.nl.

Zitieren

APA

Wilson, M. J., Schurink, A. W., Schrage, Y., Wouters, M. W. J. M., van Houdt, W. J., Grunhagen, D. J., van Thienen, H. V., van de Wiel, B. A., van der Hiel, B., & Kuijpers, A. M. J. (2026). Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116691

Vancouver

Wilson MJ, Schurink AW, Schrage Y, Wouters MWJM, van Houdt WJ, Grunhagen DJ, et al. Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116691

BibTeX
@article{Wilson2026,
  author = {Wilson, Michael J and Schurink, Antonius W and Schrage, Yvonne and Wouters, Michel W J M and van Houdt, Winan J and Grunhagen, Dirk J and van Thienen, Hans V and van de Wiel, Bart A and van der Hiel, Bernies and Kuijpers, Anke M J},
  title = {Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116691}
}
Kostenlos starten →